IRIS Accounts Production v24.2.0.383 SC763100 Board of Directors 21.3.23 31.3.24 31.3.24 false true false false false true false Ordinary shares 1.00000 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC7631002023-03-20SC7631002024-03-31SC7631002023-03-212024-03-31SC7631002023-03-20SC763100ns15:Scotland2023-03-212024-03-31SC763100ns14:PoundSterling2023-03-212024-03-31SC763100ns10:Director12023-03-212024-03-31SC763100ns10:PrivateLimitedCompanyLtd2023-03-212024-03-31SC763100ns10:SmallEntities2023-03-212024-03-31SC763100ns10:AuditExempt-NoAccountantsReport2023-03-212024-03-31SC763100ns10:SmallCompaniesRegimeForDirectorsReport2023-03-212024-03-31SC763100ns10:SmallCompaniesRegimeForAccounts2023-03-212024-03-31SC763100ns10:FullAccounts2023-03-212024-03-31SC76310012023-03-212024-03-31SC763100ns10:OrdinaryShareClass12023-03-212024-03-31SC7631001ns10:OrdinaryShareClass12023-03-212024-03-31SC763100ns10:Director22023-03-212024-03-31SC763100ns10:Director32023-03-212024-03-31SC763100ns10:Director42023-03-212024-03-31SC763100ns10:RegisteredOffice2023-03-212024-03-31SC763100ns5:CurrentFinancialInstruments2024-03-31SC763100ns5:ShareCapital2024-03-31SC763100ns5:RetainedEarningsAccumulatedLosses2024-03-31SC763100ns5:NetGoodwill2023-03-212024-03-31SC763100ns5:IntangibleAssetsOtherThanGoodwill2023-03-212024-03-31SC763100ns5:PlantMachinery2023-03-212024-03-31SC763100ns5:NetGoodwill2024-03-31SC763100ns5:PlantMachinery2024-03-31SC763100ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-31SC763100ns10:OrdinaryShareClass12024-03-31
REGISTERED NUMBER: SC763100 (Scotland)















Financial Statements for the Period 21 March 2023 to 31 March 2024

for

Gallagher Pharma Limited

Gallagher Pharma Limited (Registered number: SC763100)






Contents of the Financial Statements
for the Period 21 March 2023 to 31 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Gallagher Pharma Limited

Company Information
for the Period 21 March 2023 to 31 March 2024







DIRECTORS: K M Manson
Mrs L I M Manson
P J Manson
R J Manson





REGISTERED OFFICE: 18 North Silver Street
Aberdeen
Aberdeenshire
AB10 1JU





REGISTERED NUMBER: SC763100 (Scotland)





ACCOUNTANTS: Tawse & Partners
Chartered Accountants
18 North Silver Street
Aberdeen
AB10 1JU

Gallagher Pharma Limited (Registered number: SC763100)

Balance Sheet
31 March 2024

Notes £    £   
FIXED ASSETS
Intangible assets 5 645,739
Tangible assets 6 33,562
679,301

CURRENT ASSETS
Stocks 53,973
Debtors 7 175,013
Prepayments and accrued income 7,181
Cash at bank and in hand 189,699
425,866
CREDITORS
Amounts falling due within one year 8 1,061,063
NET CURRENT LIABILITIES (635,197 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

44,104

PROVISIONS FOR LIABILITIES 8,391
NET ASSETS 35,713

CAPITAL AND RESERVES
Called up share capital 9 100
Retained earnings 35,613
SHAREHOLDERS' FUNDS 35,713

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Gallagher Pharma Limited (Registered number: SC763100)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 October 2024 and were signed on its behalf by:





K M Manson - Director


Gallagher Pharma Limited (Registered number: SC763100)

Notes to the Financial Statements
for the Period 21 March 2023 to 31 March 2024

1. STATUTORY INFORMATION

Gallagher Pharma Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


The company's principle place of business is 8 Campfield Square, Broughty Ferry, Dundee, DD5 2PU.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at fair value of the consideration received or receivable net of VAT and discounts. The policies adopted for the recognition of turnover are as follows:

Sale of goods
Turnover from the sale of goods is recognised when significant risks and rewards of ownership of the goods
have transferred to the buyer, the amount of turnover can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services
When the outcome of a transaction can be estimated reliably, turnover from services rendered is recognised by reference to the stage of completion at the Statement of Financial Position date. Stage of completion is measured by reference to the NHS Income Statements at the Statement of Financial Position date.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2024, is being amortised evenly over its estimated useful life of ten years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on reducing balance

Stocks
Stocks are valued at the lower of cost and estimated selling price less costs to sell. Cost includes all costs of purchases, costs of conversion and other costs incurred in bring stock to its present location and condition. Provision is made for damaged, obsolete and slow-moving stock where appropriate.


Gallagher Pharma Limited (Registered number: SC763100)

Notes to the Financial Statements - continued
for the Period 21 March 2023 to 31 March 2024

3. ACCOUNTING POLICIES - continued
Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 9 .

5. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
Additions 704,442
At 31 March 2024 704,442
AMORTISATION
Amortisation for period 58,703
At 31 March 2024 58,703
NET BOOK VALUE
At 31 March 2024 645,739

Gallagher Pharma Limited (Registered number: SC763100)

Notes to the Financial Statements - continued
for the Period 21 March 2023 to 31 March 2024

6. TANGIBLE FIXED ASSETS
Plant and
machinery
£   
COST
Additions 39,887
At 31 March 2024 39,887
DEPRECIATION
Charge for period 6,325
At 31 March 2024 6,325
NET BOOK VALUE
At 31 March 2024 33,562

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Trade debtors 141,895
Other debtors 33,118
175,013

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Trade creditors 154,921
Amounts owed to group undertakings 866,290
Tax 23,090
Social security and other taxes 7,060
Other creditors 154
Accruals and deferred income 9,548
1,061,063

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal
value: £   
100 Ordinary shares 1 100

100 Ordinary shares shares of 1 each were allotted and fully paid for cash at par during the period.